Journal Article

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations

Batham, Sally, Mischler, Robert, Nicholson, Karl G., Klap, Jaco M., Wood, John M., Thompson, Catherine I., Stephenson, Iain, Zambon, Maria C., Newman, Robert W.

2009

Overview

Avian influenza H9N2 viruses are considered as a pandemic threat. We assessed the safety and immunogenicity of fourteen H9N2 vaccine formulations. A randomized, phase I trial was done in 353 adults, aged 18–82 years. Subjects received two doses of A/Hong Kong/1073/99 (H9N2) whole-virus, alum-adjuvanted whole-virus, virosomal, or intradermal whole-virus vaccine at four doses (1.7, 5, 15 or 45 μg haemagglutinin). Sera were obtained before and three weeks after each vaccination (days 0, 21, and 42) for haemagglutination–inhibition (HAI) and neutralization assays. All formulations were well tolerated. Pre-vaccination sera from subjects aged below or above 40 years had baseline antibody to H9N2 in 1% and 16% of samples. Compared to intramuscular whole-virus vaccine, alum-adjuvanted vaccine was more immunogenic, intradermal vaccine was comparable, and virosomal vaccine less immunogenic. Among subjects under 40 years, two doses (45, 15, and 5 μg) of alum-adjuvanted vaccine achieved seroprotective HAI titres in 50%, 41%, and 39% respectively, and neutralization seroconversions in 83%, 82%, and 78% of recipients. Among subjects over 40 years, one dose (45, 15, and 5 μg) of alum-adjuvanted vaccine achieved seroprotective HAI titres in 50%, 25% and 0% respectively, and neutralization seroconversions in 88%, 63% and 63% of recipients. Among immunologically naive subjects under 40 years, two doses of vaccine are required and alum-adjuvanted vaccines were most immunogenic. Among immunologically primed subjects over 40 years, one dose of whole-virus or alum-adjuvanted vaccine induced immune responses; the second dose provided less additional benefit. However, no vaccine formulation satisfied all European regulatory criteria for pandemic vaccines.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adjuvants, Immunologic - pharmacology / Adult / Age Factors / Aged / Aged, 80 and over / Allergy and Immunology / Alum Compounds - pharmacology / Antibodies / Antibodies, Viral - blood / Antibody Formation / Antigens / Avian flu / Female / Hemagglutination Inhibition Tests / Humans / Immunization, Secondary / Immunogenicity / Influenza A Virus, H9N2 Subtype - immunology / Influenza Vaccines - adverse effects / Influenza Vaccines - immunology / Influenza, Human - immunology / Influenza, Human - prevention & control / Injections, Intradermal / Male / Middle Aged / Neutralization / Neutralization Tests / Pandemic vaccine / Pandemics / Serology / Vaccines / Vaccines, Virosome - immunology / Viruses / Young Adult